Researchers from the Tisch Cancer Institute at Mount Sinai and Memorial Sloan Kettering Cancer Center have developed a new predictive AI tool that uses routine blood tests to determine patient responses to immune checkpoint inhibitors (ICIs), a type of immunotherapy.
The new tool, called SCORPIO, aims to not only improve immunotherapy outcomes by better predicting which cancer patients will benefit from ICIs but also democratize access to immunotherapy by providing a scalable and affordable alternative to genomic data.
SCORPIO uses easily available and low-cost clinical data like routine blood tests, it offers an alternative to genomic data that could more easily be adopted in resource-limited settings. Additionally, the tool supports treatment personalization, reducing the risks and costs associated with ineffective therapies, and offers insights into immune system dynamics, which could inform future research.
【MORE】